Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 | Q92731 | 1/20 | 0.56 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.49 |
| ▸ | TMEM97 | Q5BJF2 | 5/20 | 0.47 |
| ▸ | SIGMAR1 | Q99720 | 5/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.46 |
| ▸ | GPR183 | P32249 | 1/20 | 0.44 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.44 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.43 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.43 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.42 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31233739 | 1.00 | ESR2 (0.56) | ESR2NR1H2TMEM97SIGMAR1MAPT | |
| SCHEMBL31233633 | 0.91 | GPR119 (0.46) | ESR2NR1H2TMEM97SIGMAR1MAPK1 | |
| SCHEMBL23684926 | 0.83 | ESR2 (0.64) | ESR2NR1H2TMEM97SIGMAR1MAPK1 | |
| SCHEMBL30474182 | 0.81 | ESR2 (0.50) | ESR2NR1H2TMEM97SIGMAR1MAPT | |
| SCHEMBL30719471 | 0.81 | MAPT (0.52) | ESR2NR1H2MAPTMAPK1GPR119 | |
| SCHEMBL31413067 | 0.81 | ESR2 (0.50) | ESR2NR1H2TMEM97SIGMAR1MAPT | |
| SCHEMBL17893669 | 0.81 | MAPT (0.52) | ESR2NR1H2MAPTMAPK1GPR119 | |
| SCHEMBL30199590 | 0.81 | NR1H2 (0.60) | ESR2NR1H2TMEM97SIGMAR1MAPK1 | |
| SCHEMBL29852671 | 0.81 | TMEM97 (0.54) | ESR2TMEM97SIGMAR1 | |
| SCHEMBL23684873 | 0.80 | ESR2 (0.57) | ESR2NR1H2TMEM97SIGMAR1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260092076-A1 | NOVEL COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2026-04-02 | — | — | US | disclosed |
| EP-4695243-A1 | NLRP3 INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2026-02-18 | — | — | EP | disclosed |
| WO-2024213552-A1 | NLRP3 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2024-10-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260092076-A1 | NOVEL COMPOUNDS | NOD1, NLRP3, ARRB1 | ESR2 732/4885NR1H2 21/4885TMEM97 259/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.